Our skin is the largest organ in the human body, and can be affected by a multitude of different conditions and diseases. These can have profound – and in some cases, debilitating – effects on patients’ physical, functional, and emotional well-being.

The 2010 National Ambulatory Medical Care Survey reports that there are approximately 56 million annual office visits for medical dermatology conditions in the United States alone. And according to VisionGain, the medical dermatology market is expected to approach $25.5 billion in global revenues in 2015.

While the current standards of care for many dermatological conditions offer benefits and temporary relief to patients, they also possess many limitations and possible side effects, such as such as dryness, stinging, burning, and photosensitivity.

Klox Technologies has developed its proprietary and non-invasive dermatological treatment solutions to address acne vulgaris and cosmetic skin care. However, we also believe that our technology platform can be effective in the treatment of other inflammatory skin diseases, such as psoriasis, eczema, and rosacea. The nature of these pathologies suggest that they may benefit from a combination of increased collagen production, modulation of cellular response, and the production of photons and bactericidal activity.

Klox Technologies and LEO Pharma set up a company in dermatology called FB Dermatology to accelerate and further expand key geographies.

Acne is a very common and widespread skin condition that affects nearly 85% of individuals at some point in their lives. According to VisionGain, acne treatments accounted for approximately $3.7 billion of global pharmaceutical sales in 2012.

Acne sufferers are prone to clogging of the pores, long-term lesions, and associated scarring on the face, neck, chest, and back. These physical manifestations can have serious social and emotional impact on an acne sufferer’s life.

Based on our proprietary technology platform, we believe that our Kleresca/LumiCleanse treatment for acne vulgaris can improve the outcome for acne sufferers by providing effective, non-invasive, and first-line treatment.

Visit our partners at


  • Patients are not required to maintain daily treatment regiments.
  • Patients are not subjected to some of the side effects often associated with traditional oral, light-based, and systemic acne treatments.
  • Kleresca/LumiCleanse successfully completed a European registration trial and follow-up extension trial.
  • Clinical trials conducted as part of the CE mark registration have shown Kleresca/LumiCleanse to be effective at treating moderate to severe acne vulgaris, with a clean safety profile.
  • No patients experienced serious adverse events.

The cosmetic skin care market is inundated with products and procedures that claim to turn back the hands of time, from over-the-counter “anti-aging” creams to cosmetic surgery. Some of these treatments are ineffective and others may be highly invasive.

According to The International Society of Aesthetic Plastic Surgery, consumers spent more than $12 billion on over 11 million physician-administered surgical and non-surgical aesthetic procedures in the United States alone.

Based on its proprietary technology platform, Klox Technologies’ Kleresca/LumiBel for cosmetic skin care offers a non-invasive, non-abrasive, and non-thermal approach to skin care with the goal of tightening the skin and improving pore size, skin texture, and overall appearance.

Visit our partners at


  • Clinical results show an improvement in the appearance of brow, mouth, and eye region wrinkles, with high patient satisfaction.
  • No serious adverse events were reported in our clinical trial.
  • A significant majority of patients report treatment to be painless.
  • Patients are not subjected to the harmful side effects often associated with some traditional rejuvenation procedures.